Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of InVivo Therapeutics Holding Corp. (NVIV)

MBGAF, POAHY

PR Newswire

NEW YORK, July 31, 2017 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of InVivo Therapeutics Holding Corp. ("InVivo" or the "Company") (NASDAQ: NVIV). Such investors are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/nviv.

Bronstein, Gewirtz & Grossman, LLC

The investigation concerns whether InVivo and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.

On July 31, 2017, InVivo revealed that after a third patient death, it had stopped a trial of its Neuro-Spinal Scaffold, a spinal cord injury treatment and advised investors that the it had decided to stop the trial while it discusses with the U.S. Food and Drug Administration whether to change the trial's enrollment criteria. Following this news, InVivo stock dropped as much as $0.80 per share, or 32.65%, during intraday trading on July 31, 2017.

If you are aware of any facts relating to this investigation, or purchased shares of InVivo, you can assist this investigation by visiting the firm's site: www.bgandg.com/nviv. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration.   Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

 

View original content with multimedia:http://www.prnewswire.com/news-releases/shareholder-alert-bronstein-gewirtz--grossman-llc-announces-investigation-of-invivo-therapeutics-holding-corp-nviv-300496635.html

SOURCE Bronstein, Gewirtz & Grossman, LLC



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today